The effect of inositol on the improvement of primary sclerosing cholangitis patients
Phase 3
Recruiting
- Conditions
- Primary Sclerosing Cholangitis.Obstruction of bile ductK83.1
- Registration Number
- IRCT20220417054557N2
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
cholestatic liver disease for at least 6 months
serum alkaline phosphatase levels 1.5 times the normal upper limit
Exclusion Criteria
co-existing liver diseases such as alcoholic liver disease and NAFLD, autoimmune hepatitis, chronic B or C hepatitis, PBC, hemochromatosis, Wilson's disease, congenital biliary disease, and cholangiocarcinoma
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Alanine transaminase. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Aspartate aminotransferase. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Albumin. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Bilirubin. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Alkaline Phosphatase. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Alleviation of prutrius. Timepoint: before intervention and 3 month later. Method of measurement: physical examination.
- Secondary Outcome Measures
Name Time Method A decline in the Mayo Risk Score of patients. Timepoint: before intervention and 3 months later. Method of measurement: Mayo Risk scale measurement.